SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-257688
Filing Date
2022-10-04
Accepted
2022-10-04 17:28:37
Documents
16
Period of Report
2022-10-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d391688d8k.htm   iXBRL 8-K 30140
2 EX-1.1 d391688dex11.htm EX-1.1 206236
3 EX-5.1 d391688dex51.htm EX-5.1 7941
4 EX-99.1 d391688dex991.htm EX-99.1 6463
8 GRAPHIC g391688g1004220814431.jpg GRAPHIC 2412
  Complete submission text file 0001193125-22-257688.txt   433680

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA imvt-20221003.xsd EX-101.SCH 2854
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE imvt-20221003_lab.xml EX-101.LAB 17236
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE imvt-20221003_pre.xml EX-101.PRE 10811
10 EXTRACTED XBRL INSTANCE DOCUMENT d391688d8k_htm.xml XML 3223
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

IRS No.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38906 | Film No.: 221293232
SIC: 2836 Biological Products, (No Diagnostic Substances)